In a phase I/II clinical trial for NSCLC and other solid tumours, recent findings indicate that D-1553 offered 40.5% ORR, 91.9% DCR and a median progression-free survival of 8.2 months in NSCLC patients carrying KRAS G12C mutations [51]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.